Updated:
Solas BioVentures
Solas BioVentures is an SEC-registered investment adviser in Chattanooga, TN, registered since 2025.
Solas BioVentures
Solas BioVentures is an SEC-registered investment adviser in Chattanooga, TN, registered since 2025. The firm manages approximately $165 million in assets. It has 6 employees and 5 investment advisers.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chattanooga
Corporate office
Chattanooga, TN, United States
Principals
David Adair
Co-Founder & Managing Director
Mark Hackett
Co-Founder & Partner
David Belitz
Partner
Joshua Eckelberry
Partner
Travis Manasco
Partner
Michael Hoey
Co-founder (Advisory Team)
Sector focus
Frequently asked questions
Who leads investment decisions at Solas BioVentures?
Co-Founder & Managing Director David Adair and Co-Founder & Partner Mark Hackett head the investment team, alongside Partners David Belitz, Joshua Eckelberry, and Travis Manasco. The broader group includes PhD analysts and an advisory team. Decision-making appears collaborative, drawing on both in-house scientific and clinical expertise and the domain knowledge of Limited Partners.
Does Solas BioVentures invest only in the United States?
The firm's website states its reach is worldwide, and an International Relations role (held by Laurent Pacheco) confirms a global outlook. However, no specific non-US portfolio companies or offices are publicly disclosed.
Is Solas BioVentures structured as a venture capital firm or a family office?
Solas BioVentures is an SEC-registered investment adviser operating as a venture capital firm. It is not a single-family office; it manages pooled funds (Emerging Healthcare Fund series) and sidecar vehicles, and it solicits capital from external Limited Partners.
What is Solas BioVentures' known posture on co-investments?
The firm explicitly structures Solas Sidecars & Management Team SPVs, indicating a practice of offering co-investment opportunities alongside its main fund vehicles. These structures allow management and select partners to invest directly in specific deals.
Which sectors does Solas BioVentures explicitly avoid?
Solas BioVentures invests exclusively in the life science industry. The firm publishes no interest in enterprise software, consumer tech, fintech, or any sector outside biopharmaceuticals, medical devices, and digital health.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: